Seven Years of Growth Witnessed,The ICDC Brand Summit, hosted by Chujie Shengwu, has gradually become a leading annual conference in China in the fields of immuno-oncology precision medicine and companion diagnostics., The 7th International Cancer Immunotherapy Collaboration Summit (ICDC2024) will be held at the Crowne Plaza Shanghai Huamu on August 7-8, 2024,Featuring 50+ Keynote Speakers, 30+ Leading Exhibitors, and 1,000+ ProfessionalsJoin Us On-Site to Discuss Advances in Anti-Tumor Drug R&D and Treatment!
Meeting NameICDC2024: The 7th Cancer Immunotherapy Collaboration Summit
Meeting TimeAugust 7–8, 2024
Conference VenueCrowne Plaza Shanghai Huamu
OrganizerTouchBio
Scan the QR code to register for the conference (share and collect 18 likes; upload a screenshot when registering)
ATopics of the Tumor Immunology Sub-venue
A1: Tumor Immunology 2.0: Targets, Combination Therapies, and Challenges of Drug Resistance
• Focus on immunomodulatory drugs:
Immunomodulators, Immune Checkpoint Inhibitors
• Exploratory Research on Novel Targets in Tumor Immunology
• Overcoming drug resistance and enhancing immune effects to develop new combination therapies
• Applications of Immunohistochemistry in Drug Development and Diagnosis
A2: Biomarkers and Precision Medicine in Immuno-Oncology
• Development and Translation of Immuno-Oncology Drugs
• Exploration of Emerging Biomarkers in Tumor Immunology
• Key to Translational Medicine:
Application of Biomarkers from Early-Stage R&D to the Full Clinical Spectrum
• New technologies such as multi-omics and AI drive the development and validation of biomarkers
A3: “Synthetic Lethality” Breaks New Ground in Targeted Therapy
• Development of Antitumor Drugs Based on the Principle of Synthetic Lethality
• Applications of Synthetic Lethality: Overcoming Drug Resistance and Combination Therapy
• Emerging synthetic lethality targets: PRMT5, WEE1, ATR, ATM, etc.
• Strategies for Synthetic Lethality Screening and Identification in the Era of Big Data
A4: Modulating the Tumor Microenvironment and Immunotherapy
• Development of Immunotherapeutic Agents Based on Modulation of the Tumor Microenvironment
• Reshaping the tumor microenvironment:
Targeting the ECM, CAFs, and Their Activation Signaling Pathways
• Decoding the Tumor Microenvironment with New Technologies Such as Single-Cell Multi-Omics and Pathology
• Metabolic Research of the Tumor Microenvironment and Immunotherapy
BCompanion Diagnostics Session Topics
B1: Global Oncology Drug Development and CDx
• From PD-1 to ADC: Challenges and Opportunities for Chinese Innovative Drugs Going Global
• MNCs & Local Pharmaceutical Companies:
Global R&D Challenges for Novel Anti-Tumor Drugs and the Need for CDx
• Challenges and Solutions in International Multicenter Clinical Trials
• Global Registration and Regulatory Differences for Drugs and CDx
B2: Companion Diagnostics & Co-Development of Drugs
• Development of Novel Anticancer Drugs with Companion Diagnostics
• Development Pathways and Emerging Technologies for Companion Diagnostics
• Dynamic Monitoring and Companion Diagnostics of MRD
• Efficacy, Safety, and Clinical Value of CDx for Antineoplastic Drugs
B3: Focus on ADC Drug Development and Translational Medicine
• Development of Small-Molecule Conjugate "Targeted Therapeutics"
• Applications of ADC Drugs in Anti-Tumor Therapy and Development of Companion Diagnostics
• Explore biomarkers based on the target characteristics of ADCs
• Target Discovery and Translational Medicine for ADCs
B4: Research and Development of New Approaches to Antitumor Therapy and the Associated Challenges
• Overcoming the Limitations of Tumor-Targeted Drugs: Discovery of Novel Targets and Lead Compounds
• Tackling "undruggable" targets: PROTACs and molecular glues
• New Therapeutic Approaches for Tumors: Kinase Inhibitors and Radiopharmaceuticals
• AI/High-Throughput Screening Technologies Efficiently Drive Antitumor Drug Development
Photo Recap of the Conference
Contact for collaboration on keynote speeches, exhibition booths, satellite symposia, etc.
Mobile: +86 18662147488 (WeChat ID same)
EMAIL：Wilsonwang@chujietech.com
